Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study
Authors' conclusion
IDegLira significantly reduced HbA1c and FPG in this real-world setting, along with less frequent episodes of hypoglycaemia. Switching to IDegLira offers effective treatment intensification for type 2 diabetes patients with inadequate glycaemic control.
Study context
- Population
- Adults with T2D in the United Arab Emirates switching to IDegLira; mean baseline HbA1c 9.29 % (78 mmol/mol)
- Participants
- 263 adults
- Exposure
- Switching to IDegLira from Basal Insulin (BI) ± Oral Antidiabetic Drugs (OADs) or GLP-1 RA ± OADs
- BI ± OADsn = 206
- GLP-1 RA ± OADsn = 57
- Outcome
- Change in HbA1c from baseline (mixed model for repeated measurements)
- Follow-up
- 26 weeks
Methodological detailsmulticentre, real-world
- Multicentre
- Real-world
Main finding
As reported in the abstract
Change in HbA1c from baseline
BI ± OADs
−0.83
% [−9.0 mmol/mol]
GLP-1 RA ± OADs
−1.24
% [−13.5 mmol/mol]
- HbA1c significantly reduced in both groups
- both p < 0.0001
Observational data: associations, not effects.
Further findings
| Outcome | BI ± OADs | GLP-1 RA ± OADs |
|---|---|---|
| Change in FPG | −39.48 mg/dL | −82.49 mg/dL |
| Change in body weight | −1.05 kg | — not stated in the abstract |
— not stated in the abstract
- Change in fasting plasma glucose (FPG) — FPG significantly reduced in both groups
- both p < 0.0001
- Change in body weight — Body weight decreased significantly with BI ± OADs
- p < 0.0001
Safety
Hypoglycaemia, before treatment initiation vs end of study
- ≥ 1 severe hypoglycaemic episode before treatment initiation
- 3/263
- ≥ 1 non-severe hypoglycaemic episode before treatment initiation
- 7/263
- ≥ 1 severe episode at end of study
- 1/263
- ≥ 1 non-severe episode at end of study
- 1/263
Tolerability
- Treatment was well tolerated
Original publication
Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study. Diabetes Res Clin Pract. Published 24 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →